About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
B
ASCO 2021 Updated Analysis of EV-201 Cohort 2: Enfortumab Vedotin in Cisplatin-Ineligible la/mUC Who Received Prior PD-1/PD-L1 Inhibitors
By
Bradley McGregor
11 Videos
298 views
June 15, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
21:17
Janssen Oncology
The Man Cave
Feat.
J. Hamilton,
M. Fabrizio,
M. Taha
Featured Video
20:59
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Related Content
AUTOPLAY
ON
16:05
Insights from 2024 ASCO® GU Annual Meeting
Recent GU Developments and Their Clinical Implications
Feat.
T. Powles,
B. Rini
15:58
Total Health
Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024
Feat.
M. Reimers
22:19
Insights from 2023 ESMO Annual Meeting
Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …
Feat.
G. Sonpavde
14:00
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…
Feat.
G. Sonpavde
06:01
ecancer
ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…
Feat.
T. Powles
17:32
Kriti Mittal
Current Updates in Urothelial Cancer: Clinical Implications for Prac…
19:30
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
Sequencing 1L Therapies in Metastatic Urothelial Carcinoma
Feat.
P. Grivas
30:03
UCSF School of Medicine
Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…
Feat.
T. Friedlander
11:29
Oncology Data Advisor
Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…
Feat.
T. Powles
13:54
AdventHealth
FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…
Feat.
G. Sonpavde
09:12
AdventHealth
Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…
Feat.
G. Sonpavde
05:59
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Ved…
Feat.
T. Powles
15:50
Petros Grivas
Year in Review: Bladder Cancer
28:53
OncoAlert
Year in Review: Best of Bladder Cancer Updates in 2023
Feat.
A. Apolo
17:03
Total Health
Emerging Trends in Localized Bladder Cancer in 2024
Feat.
N. Gopal
12:54
Scripps MD Anderson Cancer Center
Recent Advances in Therapy for Bladder Cancer
Feat.
M. Bhangoo
05:48
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "UNITE Study - Outcomes in Patients Wit…
Feat.
A. Nizam
09:22
ASCO GU 2023 Conference Coverage
ASCO GU 2023: Dr. Park and Dr. Grivas Discuss TROPHY-U-01 and EV-201…
Feat.
P. Grivas,
C. Park
10:29
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "AMBASSADOR Alliance A031501 Study of P…
Feat.
A. Apolo
10:01
ASCO GU 2023 Conference Coverage
ASCO GU 2023 Bladder Cancer Highlights With Dr. Sonpavde and Dr. Park
Feat.
G. Sonpavde,
C. Park
